Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. (NASDAQ: HWKD) is a clinical-stage oncology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of difficult-to-treat cancers. The company applies advanced drug delivery technologies and formulation expertise to create targeted cancer therapies… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Whitehawk Therapeutics, Inc. does
In the company’s own words
Whitehawk Therapeutics, Inc. (NASDAQ: HWKD) is a clinical-stage oncology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of difficult-to-treat cancers. The company applies advanced drug delivery technologies and formulation expertise to create targeted cancer therapies designed to improve efficacy while reducing toxicity compared to existing treatments.
In December 2024, Whitehawk entered into a license agreement with WuXi Biologics and Hangzhou DAC Biotechnology to develop and commercialize a portfolio of three ADC therapies. These product candidates utilize the CPT113 linker-payload platform, which features a highly stable yet cleavable linker that delivers a Topoisomerase I inhibitor payload. The three lead programs target validated tumor antigens: HWK-007 targeting Protein Tyrosine Kinase 7 (PTK7) for solid tumors including non-small cell lung cancer and ovarian cancer; HWK-016 targeting membrane-bound Mucin 16 (MUC16) for gynecological cancers; and HWK-206, a biparatopic antibody targeting Seizure-related Protein 6 (SEZ6) for small cell lung cancer and neuroendocrine tumors. The company submitted investigational new drug applications for HWK-007 and HWK-016 in the fourth quarter of 2025, with both programs now in Phase 1 clinical trials. An IND submission for HWK-206 is anticipated in mid-2026.
Whitehawk maintains a virtual operating model utilizing outsourced clinical development and manufacturing partnerships. The company previously commercialized FYARRO (nab-sirolimus) for advanced malignant PEComa, generating $7.1 million in net product sales during 2025 before divesting the FYARRO business in March 2025 to focus resources on the ADC portfolio. The company's management team brings extensive experience in oncology drug discovery, development, and commercialization from leading pharmaceutical companies. Whitehawk is supported by top-tier life science investors and maintains operations with sufficient capital resources to fund planned operations into 2028.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MORRISTOWN, NJ
- Fiscal year end
- December
- CIK
- 1422142
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Whitehawk Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Whitehawk Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Whitehawk Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Whitehawk Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Whitehawk Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”